Details of the SBP
| General Information of Synthetic Binding Protein (SBP) (ID: SBP000156) | ||||||
|---|---|---|---|---|---|---|
| SBP Name |
DART Duvortuxizumab
|
|||||
| Synonyms |
MGD011
|
|||||
| Molecular Weight | 108.9 kDa | |||||
| Design Method | Traditional methods (Site-directed mutagenesis and/or Directed evolution) | |||||
| Highest Status | Phase I; Discontinued | |||||
| SBP Sequence |
>VH1 Chain
QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVGWIRQPPGKALEWLAHIWWDDDKR YNPALKSRLTISKDTSKNQVFLTMTNMDPVDTATYYCARMELWSYYFDYWGQGTTVTVSS >VL1 Chain ENVLTQSPATLSVTPGEKATITCRASQSVSYMHWYQQKPGQAPRLLIYDASNRASGVPSR FSGSGSGTDHTLTISSLEAEDAATYYCFQGSVYPFTFGQGTKLEIK >VH2 Chain EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYAT YYADSVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWFAYWGQGTL VTVSS >VL2 Chain QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPWT PARFSGSLLGGKAALTITGAQAEDEADYYCALWYSNLWVFGGGTKLTVL |
|||||
| Protein Scaffold Information of This SBP | ||||||
|---|---|---|---|---|---|---|
| Scaffold ID | PS028 | [1] | ||||
| Scaffold Name | DART | |||||
| Scaffold Class | Antibody fragment | |||||
| Fold Type | Beta-Sheets + Loops | |||||
| Binding Target(s) of This SBP (BTS) |
|---|
| BTS Name | Details | Mechanism | Application | Affinity | Research Organization | Ref |
|---|---|---|---|---|---|---|
| T-cell surface glycoprotein CD3 | Binder | B-cell hematological malignancies [ICD-11: 2B33.Y] | N.A. | MacroGenics | [1] | |
| B-lymphocyte antigen CD19 | Binder | B-cell hematological malignancies [ICD-11: 2B33.Y] | N.A. | MacroGenics | [1] | |
| Clinical Trial Information of This SBP | ||||||
|---|---|---|---|---|---|---|
| NCT02454270 | Click to show the Detail | |||||
| Indication | Relapsed or Refractory B-cell Malignancies | |||||
| Phase | Phase I | |||||
| Title | A Phase I, First-in-Human, Open-Label, Dose Escalation Study of Duvortuxizumab, A Humanized CD19 x CD3 Dual-Affinity Re-Targeting (DART?) Protein in Subjects With Relapsed or Refractory B-cell Malignancies | |||||
| Status | Terminated | |||||
| Sponsor | Janssen Research & Development, LLC | |||||
| NCT02743546 | Click to show the Detail | |||||
| Indication | B-Cell Malignancies | |||||
| Phase | Phase I | |||||
| Title | A Phase Ib Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of the Combination of Duvortuxizumab With Ibrutinib in Subjects With B-Cell Malignancies | |||||
| Status | Withdrawn | |||||
| Sponsor | Janssen Research & Development, LLC | |||||